Vir Biotechnology, Inc. VIR Contingent Consideration Liability (Non-Current)
Contingent Consideration Liability (Non-Current) at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent.
The official record: Vir Biotechnology, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vir Biotechnology, Inc.'s contingent consideration liability (non-current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vir Biotechnology, Inc.'s contingent consideration liability (non-current)?
- Vir Biotechnology, Inc. (VIR) reported contingent consideration liability (non-current) of $33.21M in Q1 2026.
- How has Vir Biotechnology, Inc.'s contingent consideration liability (non-current) changed year-over-year?
- Vir Biotechnology, Inc.'s contingent consideration liability (non-current) increased by 40.5% year-over-year, from $23.64M to $33.21M.
- What is the long-term trend for Vir Biotechnology, Inc.'s contingent consideration liability (non-current)?
- Over 5 years (2020 to 2025), Vir Biotechnology, Inc.'s contingent consideration liability (non-current) has grown at a 6.1% compound annual growth rate (CAGR), from $25.37M to $34.1M.
- What does contingent consideration liability (non-current) mean?
- This represents the long-term portion of estimated future payments owed to sellers following a business acquisition, typically triggered by the achievement of specific clinical, regulatory, or commercial milestones. It reflects the present value of potential earn-out obligations that are expected to be settled beyond the next twelve months. Monitoring this liability provides insight into the company's future capital commitments and the success-based valuation of its inorganic growth strategy.